Black Diamond Therapeutics, Inc. BDTX
1.60 USD -0.27 (-14.25%)
At closeNov 10, 2026, 7:27 PM EST
1.68 +0.09 +5.60%
After hours · Nov 10, 7:27 PM ET
1.58 Day range 1.91
1.58 52-week range 4.94
- YTD
- -34.36%
- 1 year
- -63.42%
News
benzinga.com Why Is Black Diamond Therapeutics Stock Soaring Tuesday? Black Diamond Therapeutics Inc. (NASDAQ:BDTX) on Tuesday reported updated Phase 2 data for its targeted cancer candidate silevertinib, detailing regulatory next steps following a pivotal U.S. Food…
benzinga.com Why Is Black Diamond Therapeutics Stock Soaring Tuesday? Black Diamond Therapeutics reports Phase 2 silevertinib data, outlines FDA Phase 3 plans, and confirms cash runway extending into late 2028.
seekingalpha.com Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript
benzinga.com Black Diamond Therapeutics Reports Updated Phase 2 Silevertinib Data, FDA End-Of-Phase 2 Feedback, Supporting Pivotal Development In All 1L EGFR-NCM NSCLC Patients With Potential For Accelerated Approval Based On CNS-ORR Updated Phase 2 results demonstrate robust CNS activity, including 86% CNS-ORR and mPFS double that of currently available EGFR TKIs, in patients with untreated brain metastasesRecent End-of-Phase 2…
globenewswire.com Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…
benzinga.com Black Diamond Therapeutics To Host A Webcast For Investors To Present Updated Results From Its Ongoing Phase 2 Trial Of Silevertinib Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including…
seekingalpha.com Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy I am downgrading Black Diamond Therapeutics from Strong Buy to 'Buy' due to slower-than-expected phase 3 initiation for silevertinib in 1st-line non-classical EGFRm NSCLC. BDTX's silevertinib…
benzinga.com HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
defenseworld.net Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX) Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
defenseworld.net Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX) Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
globenewswire.com Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of…
benzinga.com Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 10.53 percent increase over…
globenewswire.com Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…
seekingalpha.com Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and…
zacks.com BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
zacks.com Black Diamond Stock Outlook After Q1 Beat and Cash Runway BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
zacks.com BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
feeds.benzinga.com What's Going On With Black Diamond Therapeutics Stock Tuesday? Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
benzinga.com What's Going On With Black Diamond Therapeutics Stock Tuesday? Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
zacks.com BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
globenewswire.com Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…
marketbeat.com Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the…- benzinga.com Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including…
globenewswire.com Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…
globenewswire.com Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
zacks.com BDTX Shares Gain 11% in a Week: Here's What You Should Know Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
globenewswire.com Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the…
benzinga.com BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11 BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
benzinga.com Black Diamond To Present Phase 2 Data Of Silevertinib In Recurrent EGFRm NSCLC Patients And Trial-In-Progress Poster On Randomized Phase 2 Trial Of Silevertinib In EGFRvIII-Positive GBM At 2026 ASCO Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patientsTrial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients…- benzinga.com Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14 Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $13 to $14.
benzinga.com Black Diamond Therapeutic Q4 EPS $(0.27) Misses $(0.19) Estimate Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.19) by 41.36 percent. This is a 3.57 percent increase over…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals 4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
- benzinga.com Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
- benzinga.com Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
benzinga.com $3 Million Bet On Taysha Gene Therapies? Check Out These 3 Penny Stocks Insiders Are Buying The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or…- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 101 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.